Trial · NCT03743636

Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease

NCT03743636, Phase 3, Completed, Northwestern University; results first posted 2025-01-14

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease. Trials, record NCT03743636. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03743636

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease
NCT number: NCT03743636
Status: Completed
Phases: Phase 3
Enrollment: 90 participants, actual
Lead sponsor: Northwestern University
Conditions: Peripheral Artery Disease
Interventions: Nicotinamide riboside, Resveratrol, Placebo
First posted: 2018-11-16
Last updated: 2025-01-14
Results first posted: 2025-01-14

Source ClinicalTrials.gov

Registered outcomes34

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Six-minute Walk Distance (NR Alone vs. Placebo)	Baseline to 6-month follow-up	Among participants with PAD, investigators will determine whether NR alone improves six-minute walk distance at 6-month follow-up, compared to placebo.
Primary	Six-minute Walk Distance (NR/Resveratrol vs. Placebo)	Baseline to 6-month follow-up	Among participants with PAD, investigators will determine whether NR combined with resveratrol improves six-minute walk performance at 6-month follow-up, compared to placebo.
Secondary	Six-minute Walk Distance (NR Alone vs. Placebo)	Baseline to 3-month follow-up	Among participants with PAD, investigators will determine whether NR alone improves six-minute walk performance at 3-month follow-up, compared to placebo.
Secondary	Six-minute Walk Distance (NR/Resveratrol vs. Placebo)	Baseline to 3-month follow-up	Among participants with PAD, investigators will determine whether NR combined with resveratrol improves six-minute walk performance at 3-month follow-up, compared to placebo.
Secondary	Six-minute Walk Distance (NR/Resveratrol vs. NR Alone)	Baseline to 3-month follow-up	Among participants with PAD, investigators will determine whether NR combined with resveratrol improves six-minute walk performance at 3-month follow-up, compared to NR alone.
Secondary	Six-minute Walk Distance (NR/Resveratrol vs. NR Alone)	Baseline to 6-month follow-up	Among participants with PAD, investigators will determine whether NR combined with resveratrol improves six-minute walk performance at 6-month follow-up, compared to NR alone.
Secondary	Maximal Treadmill Walking Time (NR Alone vs. Placebo)	Baseline to 6-month follow-up	Among participants with PAD, investigators will determine whether NR alone improves maximal treadmill walking time at 6-month follow-up, compared to placebo.
Secondary	Walking Impairment Questionnaire (WIQ) Distance Score (NR Alone vs. Placebo)	Baseline to 6-month follow-up	Among participants with PAD, investigators will determine whether NR alone improves the Walking Impairment Questionnaire (WIQ) distance score at 6-month follow-up, compared to placebo. The WIQ is a well validated questionnaire that measures patient-reported walking limitations in distance and speed and stair-climbing. They are scored on a 0-100 scale and that 100 indicates the best possible score.
Secondary	Physical Activity (NR Alone vs. Placebo)	Baseline to 6-month follow-up	Among participants with PAD, investigators will determine whether NR alone improves physical activity at 6-month follow-up, compared to placebo. The physical activity outcome was measured with the ActiGraph, in Activity Units. Higher scores indicate greater activity. The lowest possible score is zero, indicating sedentary time.
Secondary	Maximal Treadmill Walking Time (NR/Resveratrol vs. Placebo)	Baseline to 6-month follow-up	Among participants with PAD, investigators will determine whether NR combined with resveratrol improves maximal treadmill walking time at 6-month follow-up, compared to placebo.

1 to 10 of 34Source ClinicalTrials.gov

See all 34 registered outcomes

Outcomes34

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Six-minute Walk Distance (NR Alone vs. Placebo)	Baseline to 6-month follow-up	meters	LEAST_SQUARES_MEAN
PRIMARY	Six-minute Walk Distance (NR/Resveratrol vs. Placebo)	Baseline to 6-month follow-up	meters	LEAST_SQUARES_MEAN
SECONDARY	Six-minute Walk Distance (NR Alone vs. Placebo)	Baseline to 3-month follow-up	meters	LEAST_SQUARES_MEAN
SECONDARY	Six-minute Walk Distance (NR/Resveratrol vs. Placebo)	Baseline to 3-month follow-up	meters	LEAST_SQUARES_MEAN
SECONDARY	Six-minute Walk Distance (NR/Resveratrol vs. NR Alone)	Baseline to 3-month follow-up	meters	LEAST_SQUARES_MEAN
SECONDARY	Six-minute Walk Distance (NR/Resveratrol vs. NR Alone)	Baseline to 6-month follow-up	meters	LEAST_SQUARES_MEAN
SECONDARY	Maximal Treadmill Walking Time (NR Alone vs. Placebo)	Baseline to 6-month follow-up	minutes	LEAST_SQUARES_MEAN
SECONDARY	Walking Impairment Questionnaire (WIQ) Distance Score (NR Alone vs. Placebo)	Baseline to 6-month follow-up	score on a scale	LEAST_SQUARES_MEAN
SECONDARY	Physical Activity (NR Alone vs. Placebo)	Baseline to 6-month follow-up	Activity count per day	LEAST_SQUARES_MEAN
SECONDARY	Maximal Treadmill Walking Time (NR/Resveratrol vs. Placebo)	Baseline to 6-month follow-up	minutes	LEAST_SQUARES_MEAN

1 to 10 of 34Source ClinicalTrials.gov

See all 34 outcomes

Results by group92

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Six-minute Walk Distance (NR Alone vs. Placebo)	Nicotinamide Riboside + Resveratrol	-6.93	Standard Error 7.84	meters
Six-minute Walk Distance (NR Alone vs. Placebo)	Nicotinamide Riboside + Placebo	7.00	Standard Error 8.69	meters
Six-minute Walk Distance (NR Alone vs. Placebo)	Placebo + Placebo	-10.58	Standard Error 8.45	meters
Six-minute Walk Distance (NR/Resveratrol vs. Placebo)	Nicotinamide Riboside + Resveratrol	-6.93	Standard Error 7.84	meters
Six-minute Walk Distance (NR/Resveratrol vs. Placebo)	Nicotinamide Riboside + Placebo	7.00	Standard Error 8.69	meters
Six-minute Walk Distance (NR/Resveratrol vs. Placebo)	Placebo + Placebo	-10.58	Standard Error 8.45	meters
Six-minute Walk Distance (NR Alone vs. Placebo)	Nicotinamide Riboside + Resveratrol	2.99	Standard Error 7.67	meters
Six-minute Walk Distance (NR Alone vs. Placebo)	Nicotinamide Riboside + Placebo	4.78	Standard Error 8.28	meters
Six-minute Walk Distance (NR Alone vs. Placebo)	Placebo + Placebo	-17.64	Standard Error 8.03	meters
Six-minute Walk Distance (NR/Resveratrol vs. Placebo)	Nicotinamide Riboside + Resveratrol	2.99	Standard Error 7.67	meters

1 to 10 of 92Source ClinicalTrials.gov

See all 92 results by group

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Nicotinamide Riboside + Resveratrol	33
Overall Study	STARTED	Nicotinamide Riboside + Placebo	28
Overall Study	STARTED	Placebo + Placebo	29
Overall Study	3-month Follow-up	Nicotinamide Riboside + Resveratrol	30
Overall Study	3-month Follow-up	Nicotinamide Riboside + Placebo	26
Overall Study	3-month Follow-up	Placebo + Placebo	27
Overall Study	COMPLETED	Nicotinamide Riboside + Resveratrol	33
Overall Study	COMPLETED	Nicotinamide Riboside + Placebo	28
Overall Study	COMPLETED	Placebo + Placebo	29
Overall Study	NOT COMPLETED	Nicotinamide Riboside + Resveratrol	0

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events75

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Nausea or vomiting	General disorders	Nicotinamide Riboside + Resveratrol	12	33	18
other	Nausea or vomiting	General disorders	Nicotinamide Riboside + Placebo	4	28	9
other	Nausea or vomiting	General disorders	Placebo + Placebo	7	29	8
other	Diarrhea	General disorders	Nicotinamide Riboside + Resveratrol	18	33	33
other	Diarrhea	General disorders	Nicotinamide Riboside + Placebo	11	28	20
other	Diarrhea	General disorders	Placebo + Placebo	8	29	19
other	Abdominal discomfort	General disorders	Nicotinamide Riboside + Resveratrol	13	33	21
other	Abdominal discomfort	General disorders	Nicotinamide Riboside + Placebo	11	28	22
other	Abdominal discomfort	General disorders	Placebo + Placebo	13	29	26
other	Flushing	General disorders	Nicotinamide Riboside + Resveratrol	9	33	26

1 to 10 of 75Source ClinicalTrials.gov

See all 75 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Nicotinamide Riboside + Resveratrol	0	33
Total, all-cause mortality	Nicotinamide Riboside + Placebo	0	28
Total, all-cause mortality	Placebo + Placebo	0	29
Total, other adverse events	Nicotinamide Riboside + Resveratrol	24	33
Total, other adverse events	Nicotinamide Riboside + Placebo	18	28
Total, other adverse events	Placebo + Placebo	21	29
Total, serious adverse events	Nicotinamide Riboside + Resveratrol	9	33
Total, serious adverse events	Nicotinamide Riboside + Placebo	6	28
Total, serious adverse events	Placebo + Placebo	6	29

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
36588397	DERIVED	PubMed
42035974	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03743636

GET https://conductscience.org/api/trials/v1/NCT03743636/registered?page=2

API reference For AI assistants